Viral Vector Manufacturing Market Forecasts to 2028 – Global Analysis By Type (Pox Virus, Cytomegalovirus, Herpes Simplex Virus Vectors, Adenoviral Vectors), Application (Gene Therapy, Vaccinology) and By Geography
According to Stratistics MRC, the Global Viral Vector Manufacturing Market is accounted for $566.51 million in 2021 and is expected to reach $1,804.59 million by 2028 growing at a CAGR of 18.0% during the forecast period. Viral vectors are manufactured for delivering genetic materials into the target cells in various genetic, vaccinology, and molecular biology applications. Also, viral vectors are exploited for discovering various therapeutic areas. Viral vectors are manufactured using viruses and animal or insect cell cultures.
Increasing prevalence of infectious diseases
The growing worldwide burden of cancer, infectious diseases, and genetic disorders is increasing in several countries and therefore acting as the biggest driver of the market. Factors driving market growth include the increasing prevalence of genetic diseases, cancer, and infectious diseases, the increasing number of clinical trials of viral vectors, and the availability of funding for gene therapy development. The Viral Vector Manufacturing Market is growing significantly due to a rise in the number of gene therapy-based products in the market.
Short life of viral vectors
Viral vectors come with the disadvantage of having a short life. This is expected to have a negative impact on the growth of the market. Moreover, the high cost of gene-based medical therapies might hamper the demand for viral vectors during the forecast period.
Emergence of molecular biology
The emergence of molecular biology is accelerating genomic sequencing that is further expected to reinforce precision medicine. The progress showcased by molecular biology and medical science are aligning gene therapy to a progressive borderline, thereby fostering the growth of the viral vector manufacturing for revolutionizing patient care. Moreover, with their increasing use in gene therapy for the treatment of several diseases such as cancer, metabolic diseases, and others, the demand for viral vector manufacturing is projected to rise.
Highly regulated processes
Tedious and highly regulated processes for vector production and inadequate capacity for vector production are some of the key challenges in the market for viral vectors and plasmid DNA manufacturing. To overcome these challenges, more focused attempts are required.
The vaccinology segment is expected to be the largest during the forecast period
High employment of viral vectors in vaccine development owing to their efficiency-related advantages is the main factor driving the vaccinology sector. Some advantages are the potential to elicit a wide immune response, safety profiles, and easy manufacturing. The recent outbreak of the COVID-19 virus has driven the use of viral vectors in vaccine development. Although viral vectors were widely used for vaccine development before the emergence of COVID-19, the urgency to develop a vaccine against this virus has led the scientific community to repurpose the existing approaches. Non-replicating viral vectors are being used in the COVID-19 viral vector vaccines. Various companies have launched platforms for the clinical trial base manufacturing for addressing the bottlenecks associated with the viral vector supply chain amidst the pandemic situation. Such initiatives are attributive to drive manufacturing and research practices in viral vector academic organizations and CROs .
The research institutes segment is expected to have the highest CAGR during the forecast period
The increasing involvement of the research community in gene and cell therapy research activities is expected to increase the demand for viral vectors in the global market. An increase in the introduction of advanced therapies along with the rising number of gene therapy-based R&D programs by companies, pharmaceutical, and biopharmaceutical companies are emerging as the significant end-users of the market for viral vectors and plasmid DNA manufacturing. For instance, Abeona Therapeutics is one of such companies that is actively evaluating AAV9-based gene therapies for CLN1 and CLN3 diseases.
Region with largest share:
North America is projected to hold the largest market share owing to the high adoption rate of new therapies and the high incidence rate of cancer. The increasing prevalence of genetic and other chronic disorders, an aging population, growing demand for targeted and personalized medicine, and favorable government initiatives are the factors responsible for future market growth in the region. Many companies have been expanding their facilities and investing a significant amount of capital in the region. Educational and academic institutes have also been at the forefront of R&D investment. For instance, Harvard University announced that it was collaborating with contract development and manufacturing organizations (CDMOs) to develop a USD 50 million cell and viral vector manufacturing facility. Such initiatives are expected to boost the market growth in North America.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR due to the increasing research activities for the introduction of novel gene therapies in the untapped markets of this region. The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia Pacific viral vector manufacturing market. The viral vector manufacturing market is also driven by the government approvals to conduct trials related to the Ebola virus disease vaccine. An increasing number of clinical trials related to viral vector vaccine in China also drives the growth of the viral vector manufacturing market in this country.
Key players in the market
Some of the key players profiled in the Viral Vector Manufacturing Market include Merck KGaA, Thermo Fisher Scientific Inc., Brammer Bio, Spark Therapeutics, Fujifilm Holdings Corporation, Lonza, Kaneka Eurogentec, Finvector Vision Therapies, Cobra Biologics, Uniqure, Oxford Biomedica, Massbiologics, Novasep, Regenxbio, and Shape Therapeutics.
In January 2021: Thermo Fisher Scientific acquired Viral Vector’s manufacturing business of Henogen SA, Novasep’s in Belgium, for approximately EUR 725 million.
In January 2021: Fujifilm Corporation announced plans to invest USD 40 million, which will be used to establish a new processing facility for viral vector manufacturing and associated research.
In December 2020: Shape Therapeutics launched an innovative capsid discovery platform designed to improve the delivery and safety of gene therapies. The platform could generate adeno-associated virus (AAV) vectors that are tissue-specific.
In April 2020: Merck KgaA and its subsidiary MilliporeSigma announced plans to spend USD 110 million to open a second viral vector facility at its Carlsbad, California facility.
• Human Disease
• Veterinary Disease
• Pox Virus
• Herpes Simplex Virus Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retroviral Vectors
• Gene Therapy
End Users Covered:
• Biotech Companies
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
• North America
o Rest of Europe
• Asia Pacific
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 Executive Summary
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
3 Market Trend Analysis
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Viral Vector Manufacturing Market, By Disease
5.2 Human Disease
5.2.1 Genetic Disorders
126.96.36.199 Human Immunodeficiency Virus (HIV)
5.2.3 Infectious Diseases
5.3 Veterinary Disease
5.3.1 Infectious Bronchitis
5.3.2 Avian Influenza
5.3.3 Marek's Disease
5.3.4 Peste des Petits Ruminants (PPR) Disease
5.3.5 Other Veterinary Diseases
188.8.131.52 Newcastle Disease
184.108.40.206 Swine Influenza
220.127.116.11 Equine Influenza
18.104.22.168 Fibromuscular Dysplasia (FMD)
6 Global Viral Vector Manufacturing Market, By Type
6.2 Pox Virus
6.4 Herpes Simplex Virus Vectors
6.5 Adenoviral Vectors
6.6 Adeno-Associated Viral Vectors
6.7 Retroviral Vectors
6.7.1 Lentiviral Vectors
6.7.2 Gamma-Retroviral Vectors
7 Global Viral Vector Manufacturing Market, By Application
7.2 Gene Therapy
7.3.1 Multivalent Vaccines
7.3.2 Multipathogen Vaccines
8 Global Viral Vector Manufacturing Market, By End User
8.2 Biotech Companies
8.3 Pharmaceutical and Biopharmaceutical Companies
8.4 Research Institutes
9 Global Viral Vector Manufacturing Market, By Geography
9.2 North America
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.5 Other Key Strategies
11 Company Profiling
11.1 Merck KGaA
11.2 Thermo Fisher Scientific Inc.
11.3 Brammer Bio
11.4 Spark Therapeutics
11.5 Fujifilm Holdings Corporation
11.7 Kaneka Eurogentec
11.8 Finvector Vision Therapies
11.9 Cobra Biologics
11.11 Oxford Biomedica
11.15 Shape Therapeutics
List of Tables
1 Global Viral Vector Manufacturing Market Outlook, By Region (2020-2028) ($MN)
2 Global Viral Vector Manufacturing Market Outlook, By Disease (2020-2028) ($MN)
3 Global Viral Vector Manufacturing Market Outlook, By Human Disease (2020-2028) ($MN)
4 Global Viral Vector Manufacturing Market Outlook, By Genetic Disorders (2020-2028) ($MN)
5 Global Viral Vector Manufacturing Market Outlook, By Cancer (2020-2028) ($MN)
6 Global Viral Vector Manufacturing Market Outlook, By Infectious Diseases (2020-2028) ($MN)
7 Global Viral Vector Manufacturing Market Outlook, By Veterinary Disease (2020-2028) ($MN)
8 Global Viral Vector Manufacturing Market Outlook, By Infectious Bronchitis (2020-2028) ($MN)
9 Global Viral Vector Manufacturing Market Outlook, By Avian Influenza (2020-2028) ($MN)
10 Global Viral Vector Manufacturing Market Outlook, By Marek's Disease (2020-2028) ($MN)
11 Global Viral Vector Manufacturing Market Outlook, By Peste des Petits Ruminants (PPR) Disease (2020-2028) ($MN)
12 Global Viral Vector Manufacturing Market Outlook, By Other Veterinary Diseases (2020-2028) ($MN)
13 Global Viral Vector Manufacturing Market Outlook, By Type (2020-2028) ($MN)
14 Global Viral Vector Manufacturing Market Outlook, By Pox Virus (2020-2028) ($MN)
15 Global Viral Vector Manufacturing Market Outlook, By Cytomegalovirus (2020-2028) ($MN)
16 Global Viral Vector Manufacturing Market Outlook, By Herpes Simplex Virus Vectors (2020-2028) ($MN)
17 Global Viral Vector Manufacturing Market Outlook, By Adenoviral Vectors (2020-2028) ($MN)
18 Global Viral Vector Manufacturing Market Outlook, By Adeno-Associated Viral Vectors (2020-2028) ($MN)
19 Global Viral Vector Manufacturing Market Outlook, By Retroviral Vectors (2020-2028) ($MN)
20 Global Viral Vector Manufacturing Market Outlook, By Lentiviral Vectors (2020-2028) ($MN)
21 Global Viral Vector Manufacturing Market Outlook, By Gamma-Retroviral Vectors (2020-2028) ($MN)
22 Global Viral Vector Manufacturing Market Outlook, By Application (2020-2028) ($MN)
23 Global Viral Vector Manufacturing Market Outlook, By Gene Therapy (2020-2028) ($MN)
24 Global Viral Vector Manufacturing Market Outlook, By Vaccinology (2020-2028) ($MN)
25 Global Viral Vector Manufacturing Market Outlook, By Multivalent Vaccines (2020-2028) ($MN)
26 Global Viral Vector Manufacturing Market Outlook, By Multipathogen Vaccines (2020-2028) ($MN)
27 Global Viral Vector Manufacturing Market Outlook, By End User (2020-2028) ($MN)
28 Global Viral Vector Manufacturing Market Outlook, By Biotech Companies (2020-2028) ($MN)
29 Global Viral Vector Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2020-2028) ($MN)
30 Global Viral Vector Manufacturing Market Outlook, By Research Institutes (2020-2028) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: firstname.lastname@example.org or phone: +1-301-202-5929
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at email@example.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
Select License Type
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.